The contributions of these findings include confirmation of the incidence of community-onset MRSA pneumonia and quantification of risk-adjusted attributable excess costs using a multicenter sample.Bycombiningthesefindingswithepidemiologicdata(such as the total annual number of community-onset pneumonia inpatients) in future research, we can obtain nationwide estimates of the economic burden of community-onset MRSA pneumonia inpatients. This can provide basic descriptive statistics to serve as a referenceforsupportingfurtherresearchonmultidrug-resistantbacterialinfections,andinformpolicyformulationtoreducetheburden of these infections.